MX2019002616A - Compuesto de anillo aromatico de pirido de cinco elementos, metodo de preparacion y uso del mismo. - Google Patents

Compuesto de anillo aromatico de pirido de cinco elementos, metodo de preparacion y uso del mismo.

Info

Publication number
MX2019002616A
MX2019002616A MX2019002616A MX2019002616A MX2019002616A MX 2019002616 A MX2019002616 A MX 2019002616A MX 2019002616 A MX2019002616 A MX 2019002616A MX 2019002616 A MX2019002616 A MX 2019002616A MX 2019002616 A MX2019002616 A MX 2019002616A
Authority
MX
Mexico
Prior art keywords
pyrido
preparation
aromatic ring
method therefor
ring compound
Prior art date
Application number
MX2019002616A
Other languages
English (en)
Inventor
Geng Meiyu
Chen Yi
Ding Jian
Jiang Lei
Cao Jianhua
Chen Xuxing
Yao Yucai
Jiang Qingyun
Shen Qianqian
Zhao Zhao
Xiong Yuanfang
Original Assignee
Shanghai Haihe Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shanghai Haihe Pharmaceutical Co Ltd filed Critical Shanghai Haihe Pharmaceutical Co Ltd
Publication of MX2019002616A publication Critical patent/MX2019002616A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Abstract

La presente invención proporciona un compuesto de pirido de anillo aromático de cinco elementos, y un método de preparación para el mismo, así como el del mismo. El compuesto proporcionado en la presente invención tiene un efecto inhibidor sobre EZH2 de tipo salvaje o mutante, y está bien posicionado para convertirse en un nuevo fármaco antitumoral o un fármaco para el tratamiento de enfermedades autoinmunes.
MX2019002616A 2016-09-07 2017-09-06 Compuesto de anillo aromatico de pirido de cinco elementos, metodo de preparacion y uso del mismo. MX2019002616A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201610807947 2016-09-07
PCT/CN2017/100747 WO2018045971A1 (zh) 2016-09-07 2017-09-06 吡啶并五元芳香环类化合物、其制备方法及用途

Publications (1)

Publication Number Publication Date
MX2019002616A true MX2019002616A (es) 2019-09-18

Family

ID=61561814

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019002616A MX2019002616A (es) 2016-09-07 2017-09-06 Compuesto de anillo aromatico de pirido de cinco elementos, metodo de preparacion y uso del mismo.

Country Status (12)

Country Link
US (1) US10968215B2 (es)
EP (1) EP3524602A1 (es)
JP (1) JP6816287B2 (es)
KR (1) KR102351782B1 (es)
CN (1) CN109790160B (es)
AU (1) AU2017323112B2 (es)
CA (1) CA3036114A1 (es)
EA (1) EA038701B1 (es)
MA (1) MA46199A (es)
MX (1) MX2019002616A (es)
WO (1) WO2018045971A1 (es)
ZA (1) ZA201901827B (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110229151B (zh) 2018-03-06 2021-09-10 上海海和药物研究开发股份有限公司 吲嗪类化合物、其制备方法及用途
US20220024941A1 (en) 2019-03-25 2022-01-27 Shanghai Synergy Pharmaceutical Sciences Co., Ltd. Preparation Method for Amide Compounds and Use Thereof in Medical Field
EP4306522A1 (en) * 2021-03-11 2024-01-17 Zhejiang University Fused ring heterocyclic compound and application thereof, and pharmaceutical composition containing same and application thereof

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8334001D0 (en) * 1983-12-21 1984-02-01 May & Baker Ltd Compositions of matter
FR2805539B1 (fr) * 2000-02-25 2005-06-10 Oreal Compositions de teinture des fibres keratiniques contenant des derives d'indolizine et procede de teinture
MY136840A (en) * 2002-09-19 2008-11-28 Schering Corp Pyrazolopyridines as cyclin dependent kinase inhibitors
US20050049276A1 (en) * 2003-07-23 2005-03-03 Warner-Lambert Company, Llc Imidazopyridines and triazolopyridines
MX2009007302A (es) 2007-01-23 2009-07-15 Palau Pharma Sa Derivados de purina.
PT2415771E (pt) * 2009-03-31 2013-10-03 Kissei Pharmaceutical Derivado de indolizina e sua utilização para fins médicos
US8846935B2 (en) * 2010-05-07 2014-09-30 Glaxosmithkline Llc Indazoles
CA2809112A1 (en) 2010-09-03 2012-03-08 Dainippon Sumitomo Pharma Co., Ltd. Cyclic amide derivative
US8765792B2 (en) * 2010-12-01 2014-07-01 Glaxosmithkline Llc Indoles
AU2012223448B2 (en) * 2011-02-28 2017-03-16 Epizyme, Inc. Substituted 6,5-fused bicyclic heteroaryl compounds
AU2012315566A1 (en) * 2011-09-30 2014-04-17 Glaxosmithkline Llc Methods of treating cancer
BR112014010803A2 (pt) * 2011-11-04 2017-04-25 Glaxosmithkline Intellectual Property (No 2) Ltd método de tratamento
EA030196B1 (ru) 2013-04-30 2018-07-31 Глэксосмитклайн Интеллекчуал Проперти (No.2) Лимитед Ингибиторы энхансера zeste гомолога 2
WO2015010049A1 (en) 2013-07-19 2015-01-22 Epizyme, Inc. Substituted benzene compounds
WO2015023915A1 (en) 2013-08-15 2015-02-19 Constellation Pharmaceuticals, Inc. Indole derivatives as modulators of methyl modifying enzymes, compositions and uses thereof
WO2015077193A1 (en) 2013-11-19 2015-05-28 Bristol-Myers Squibb Company Inhibitors of lysine methyl transferase
WO2015110999A1 (en) 2014-01-24 2015-07-30 Piramal Enterprises Limited Ezh2 inhibitors and uses thereof
WO2015200650A1 (en) 2014-06-25 2015-12-30 Epizyme, Inc. Substituted benzene and 6,5-fused bicyclic heteroaryl compounds
WO2016102493A1 (en) * 2014-12-22 2016-06-30 Bayer Pharma Aktiengesellschaft Imidazopyridine ezh2 inhibitors

Also Published As

Publication number Publication date
EP3524602A1 (en) 2019-08-14
EA201990645A1 (ru) 2019-08-30
AU2017323112B2 (en) 2020-11-26
US20190211010A1 (en) 2019-07-11
JP6816287B2 (ja) 2021-01-20
CN109790160A (zh) 2019-05-21
ZA201901827B (en) 2021-07-28
US10968215B2 (en) 2021-04-06
CA3036114A1 (en) 2018-03-15
JP2019530740A (ja) 2019-10-24
KR102351782B1 (ko) 2022-01-17
EA038701B1 (ru) 2021-10-07
AU2017323112A1 (en) 2019-03-28
KR20190077327A (ko) 2019-07-03
MA46199A (fr) 2019-07-17
CN109790160B (zh) 2022-11-15
WO2018045971A1 (zh) 2018-03-15

Similar Documents

Publication Publication Date Title
MX2019003735A (es) Formulaciones diluibles de cannabinoides y procesos para su preparacion.
MX2018002017A (es) Compuestos de anillo de imidazo[4,5-c] sustituido con guanidina.
MX2021013837A (es) Enfoque de inmunoterapias de combinacion para el tratamiento del cancer.
MX2019007648A (es) Composiciones y metodos para la induccion de celulas t cd8+.
WO2016109546A3 (en) Methods and compositions for prognosis and treatment of cancers
EP3389725A4 (en) COMPOSITIONS AND METHOD FOR THE TREATMENT OF DISEASES OF THE CENTRAL NERVOUS SYSTEM
GEP20247593B (en) Compositions and methods of inhibiting masp-3 for the treatment of various diseases and disorders
PH12016502256A1 (en) Medical use
MA39717A (fr) Procédés et compositions pour accroître le rapport des lymphocytes t effecteurs aux lymphocytes t régulateurs
NZ735044A (en) Condensed ring derivative, and preparation method, intermediate, pharmaceutical composition and use thereof
EP3429605A4 (en) THERAPEUTIC AGENT FOR THE TREATMENT OF DISEASES, IN PARTICULAR DISEASES AFFECTING THE CENTRAL NERVOUS SYSTEM
MX2020005567A (es) Metodos de tratamiento con asparaginasa.
PH12016502291A1 (en) Indolizine derivatives as phosphoinositide 3-kinases inhibitors
EP3195866A4 (en) Pharmaceutical composition for treating flt3 mutation-positive cancer, flt3 mutant inhibitor, and use of said pharmaceutical composition and said inhibitor
PH12020500105A1 (en) Bicyclic ketone compounds and methods of use thereof
MY194314A (en) Heterocyclic derivatives and use thereof
SG10201810660QA (en) Alkyl derivatives of 1-oxa-4,9-diazaspiro undecane compounds having multimodal activity against pain
MX2017015225A (es) Inhibidores de la autotaxina y sus usos.
MX2019002616A (es) Compuesto de anillo aromatico de pirido de cinco elementos, metodo de preparacion y uso del mismo.
PH12018502154A1 (en) Methods of treating ocular conditions
MX2022006817A (es) Formulaciones/composiciones que comprenden un inhibidor de btk.
MX2017014456A (es) Usos terapeuticos de l-4-cloroquinurenina.
ZA201703467B (en) Methods of treating ocular conditions
PH12019550183A1 (en) Treatment of infant colic
MX2017016346A (es) Metodos de tratamiento con taselisib.